• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors

    5/12/22 1:00:00 PM ET
    $AERC
    $NVCR
    $PODD
    $RNLX
    Environmental Services
    Utilities
    Medical/Dental Instruments
    Health Care
    Get the next $AERC alert in real time by email

    PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee.

    Mr. Scannell brings over 30 years of experience and success delivering market-leading results from his leadership roles at Stryker Corporation (NYSE:SYK) ("Stryker"), one of the world's leading medical technology companies. Mr. Scannell served as President and Chief Operating Officer of Stryker between 2018 and 2021, overseeing all of Stryker's commercial businesses and regions globally. Prior to this, he served as group president for Stryker's MedSurg & Neurotechnology businesses for ten years. Mr. Scannell currently serves as a director and non-executive chairman of the Board of Directors for Insulet Corporation (NASDAQ:PODD) and is a director on the boards of Novocure Limited (NASDAQ:NVCR), Renalytix plc (NASDAQ:RNLX) and Collagen Matrix, Inc.

    "Tim Scannell is a medical technology industry veteran with vast experience and a tremendous track record of success. He drove market leading sales and supported Stryker's top tier M&A results during his time at Stryker. He will be a great addition to our Board," said Jason DiBona, AeroClean's Chief Executive Officer. "Tim's interest in joining our Board and helping advance our mission is a testament to our Company's vision. I welcome Tim to the team and look forward to his contributions to the success of AeroClean."

    "I am proud to join the Board of AeroClean. I look forward to supporting and advancing AeroClean's mission of keeping life going with healthy, safe air solutions," said Mr. Scannell. "I am energized by AeroClean's mission, impressed by their board and management team, and enthusiastic about the Company's opportunity to build a great business with tremendous impact on millions of lives in the years to come."

    About AeroClean Technologies

    AeroClean is a pathogen elimination technology company on a mission to keep work, play and life going—with continuous air sanitization products called Pūrgo™ (pure-go). We create solutions for hospitals, offices, and many shared spaces as well as elevators and more. Pūrgo™ products feature SteriDuct™, a proprietary technology developed by our best-in-class aerospace engineers, medical scientists and innovators. Powered by SteriDuct™, our solutions are medical grade, eradicating viral, fungal and bacterial airborne pathogens. Our purpose is simple: to never stop innovating solutions that keep people healthy and safe, so life never stops. Learn more at aeroclean.com.

    Media Contact

    Drew Tybus

    [email protected]

    Investor Relations Contacts

    Ryan Tyler

    Chief Financial Officer, AeroClean

    [email protected]

    Brian Pinkston

    MATTIO Communications

    [email protected]



    Primary Logo

    Get the next $AERC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AERC
    $NVCR
    $PODD
    $RNLX

    CompanyDatePrice TargetRatingAnalyst
    NovoCure Limited
    $NVCR
    7/8/2025$30.00Buy
    Ladenburg Thalmann
    Insulet Corporation
    $PODD
    6/16/2025$365.00Buy
    Truist
    Insulet Corporation
    $PODD
    5/30/2025$380.00Buy
    Goldman
    Insulet Corporation
    $PODD
    5/13/2025$350.00Peer Perform → Outperform
    Wolfe Research
    Insulet Corporation
    $PODD
    4/29/2025Outperform → Peer Perform
    Wolfe Research
    Insulet Corporation
    $PODD
    3/6/2025$340.00Outperform
    RBC Capital Mkts
    Stryker Corporation
    $SYK
    2/26/2025$450.00Buy
    Citigroup
    Stryker Corporation
    $SYK
    12/2/2024$370.00 → $445.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $AERC
    $NVCR
    $PODD
    $RNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Human Resources Officer Puri Michal Nath was granted 833 units of Ordinary Shares, increasing direct ownership by 0.51% to 164,514 units (SEC Form 4)

      4 - NovoCure Ltd (0001645113) (Issuer)

      7/1/25 4:20:52 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Director Danziger Asaf was granted 833 units of Ordinary Shares, increasing direct ownership by 0.20% to 416,473 units (SEC Form 4)

      4 - NovoCure Ltd (0001645113) (Issuer)

      7/1/25 4:19:41 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • EVP, Pres., Novocure Oncology Leonard Frank X was granted 833 units of Ordinary Shares, increasing direct ownership by 0.24% to 348,711 units (SEC Form 4)

      4 - NovoCure Ltd (0001645113) (Issuer)

      7/1/25 4:19:49 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      8/29/24 4:17:26 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

      4 - INSULET CORP (0001145197) (Issuer)

      9/21/23 4:48:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 18, 2024 - FDA Roundup: October 18, 2024

      For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

      10/18/24 4:16:25 PM ET
      $NVCR
      $BAX
      Medical/Dental Instruments
      Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on NovoCure with a new price target

      Ladenburg Thalmann initiated coverage of NovoCure with a rating of Buy and set a new price target of $30.00

      7/8/25 8:49:22 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Truist initiated coverage on Insulet with a new price target

      Truist initiated coverage of Insulet with a rating of Buy and set a new price target of $365.00

      6/16/25 7:50:27 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on Insulet with a new price target

      Goldman initiated coverage of Insulet with a rating of Buy and set a new price target of $380.00

      5/30/25 8:41:35 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by NovoCure Limited

      SCHEDULE 13G/A - NovoCure Ltd (0001645113) (Subject)

      7/7/25 1:42:49 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by NovoCure Limited

      S-8 POS - NovoCure Ltd (0001645113) (Filer)

      6/30/25 4:15:25 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by NovoCure Limited

      S-8 POS - NovoCure Ltd (0001645113) (Filer)

      6/30/25 4:15:14 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2

      7/8/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Stryker to announce financial results for its second quarter of fiscal year 2025

      Portage, Michigan, July 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its second quarter of fiscal year 2025 on Thursday, July 31, 2025.  A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's second quarter that ended June 30, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, July 31, 2025, to discuss its second quarter 2025 results.  The webcast can be accessed at Stryker - Events & Presentations.  An archive of the webcast will also be available on the company's website two hours after

      7/1/25 8:00:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

      TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated a statistically significant and clinically meaningful benefit across multiple measures of pain and in a post-hoc analysis significantly delayed the need for opioid pain medication for patients with unresectable, locally advanced pancreatic adenocarcinoma A significant delay in deterioration across measures of health status was observed, preserving quality of life longer in patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel These data complement the previously reported overall survival benefit seen in PANOVA-3, supporting TTFields concomitant with gemcitabine and nab-paclitax

      7/1/25 7:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Insulet Appoints Ashley McEvoy President and CEO

      Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig

      4/28/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

      Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev

      3/11/25 8:03:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Insulet to Host Investor Day on June 5, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company

      3/11/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      11/12/24 12:53:28 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      10/7/24 11:37:08 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Renalytix plc

      SC 13D/A - Renalytix plc (0001811115) (Subject)

      10/2/24 8:05:02 PM ET
      $RNLX
      Medical Specialities
      Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Financials

    Live finance-specific insights

    See more
    • Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2

      7/8/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Novocure to Report Second Quarter 2025 Financial Results

      Novocure (NASDAQ:NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the company's financial results for the three- and six-month periods that ended June 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.novocure.co

      6/30/25 7:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

      Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P

      5/8/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care